Diabetes
RCT | Insulin Glargine vs. Glimepiride vs. Sitagliptin vs. Liraglutide resulted in similar microvascular outcomes and death rates in patients with Type 2 diabetes not controlled with metformin.
22 Sep, 2022 | 13:20h | UTCGlycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes – New England Journal of Medicine (link to abstract – $ for full-text)
Related Study: Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes – New England Journal of Medicine
News Release: Two popular diabetes drugs outperformed others in large clinical trial – National Institutes of Health
Study shows that the leading causes of hospitalization of adults with diabetes are changing.
22 Sep, 2022 | 13:08h | UTCCommentaries:
The changing character of diabetes complications – The Lancet Diabetes & Endocrinology (free registration required)
Reasons for hospital admissions in people with type 2 diabetes are changing – MedicalXpress
RCT | Open-source automated insulin delivery in Type 1 Diabetes.
19 Sep, 2022 | 12:41h | UTCOpen-Source Automated Insulin Delivery in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Video summary: Open-Source Automated Insulin Delivery in Type 1 Diabetes – NEJM
Commentaries:
Automated Insulin Delivery Ups Time in Target Glucose Range in T1D – HealthDay
Cohort Study | Patients diagnosed with diabetes by oral glucose tolerance test without elevated HbA1c had similar cardiovascular and renal disease risks as those without diabetes.
15 Sep, 2022 | 13:12h | UTC
Commentary on Twitter
#OriginalResearch: Oral glucose tolerance test diagnosed #diabetes were not confirmed by HbA1c during 4 year follow-up. Cases without HbA1c confirmation had similar vascular risk as the diabetes-free population. @whitehall2study @MikaKivimaki #AHAJournals https://t.co/ujC8cjRS7S pic.twitter.com/CRR3zlm5x2
— Circulation (@CircAHA) August 30, 2022
Consensus recommendations for the use of Automated Insulin Delivery (AID) technologies in clinical practice.
15 Sep, 2022 | 13:06h | UTC
USPSTF Statement | The current evidence is insufficient to recommend routine screening for prediabetes and type 2 diabetes in children and adolescents.
14 Sep, 2022 | 13:23h | UTCEditorials:
Recommendations for Screening Children and Adolescents for Prediabetes and Type 2 Diabetes – JAMA
Broader Screening for Youth-Onset Type 2 Diabetes—We Just Are Not There Yet – JAMA Network Open
Patient Page: Screening for Type 2 Diabetes in Children and Adolescents – JAMA
Author Interview: USPSTF Recommendation: Screening for Prediabetes and Diabetes in Children and Adolescents – JAMA
Cluster RCT | Tighter vs. less tight glycemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity.
13 Sep, 2022 | 13:21h | UTC
RCT | In youths with new-onset type 1 diabetes, intensive glucose control for 24 months with a closed-loop system did not help to preserve pancreatic function.
11 Sep, 2022 | 22:57h | UTCClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Preservation of C-Peptide Secretion Examined in Youth With T1D – HealthDay
Commentary on Twitter (video summary)
In patients with newly diagnosed type 1 diabetes, it is uncertain whether intensive glucose control can prevent the decline in endogenous insulin secretion. New research findings are summarized in a short video. https://t.co/gJeYus4G5z pic.twitter.com/igclSnyanu
— NEJM (@NEJM) September 10, 2022
A randomized crossover trial with 12 patients showed that a bihormonal “artificial pancreas” with closed-loop glucose control increases patients’ time on euglycemia after total pancreatectomy.
11 Sep, 2022 | 22:45h | UTCBihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary: Novel Bihormonal Artificial Pancreas Beneficial After Pancreatectomy – HealthDay
Study shows bariatric surgery is more effective than lifestyle for type 2 diabetes remission.
8 Sep, 2022 | 14:27h | UTCNews Release: Bariatric surgery more effective than lifestyle for type 2 diabetes remission – Pennington Biomedical Research Center
Original Study: Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) – Diabetes Care
RCT | Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes.
7 Sep, 2022 | 12:30h | UTCAdvanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study – The Lancet Endocrinology (link to abstract – $ for full-text)
Commentary: ‘Artificial Pancreas’ Best in Poorly Controlled Type 1 Diabetes – Medscape (free registration required)
Commentary on Twitter
New—Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 #diabetes (ADAPT): a randomised controlled study https://t.co/XrrmoDuQLy #T1D pic.twitter.com/GSLWA3xX7F
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) September 2, 2022
RCT | The effect of a liberal approach to glucose control in critically ill patients with type 2 diabetes.
1 Sep, 2022 | 11:37h | UTCThe Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A multicenter, parallel-group, open-label, randomized clinical trial – American Journal of Respiratory and Critical Care Medicine (link to abstract – $ for full-text)
Commentary from the author on Twitter
Excited to share results of the LUCID trial! A liberal approach to blood glucose targets reduced incidence hypoglycemia but did not improve patient-centered outcomes. https://t.co/HO53nzfBQT@MelbourneICU @CRENutrition @BellomoRinaldo @icurah @DogICUma @Eastwoodgm @MACHAustralia
— Alex Poole (@AlexPPoole) May 25, 2022
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.
30 Aug, 2022 | 11:59h | UTCAcute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
Update on the management of diabetes in long-term care facilities.
26 Aug, 2022 | 13:23h | UTC
Randomized Crossover Trial | In patients with diabetic neuropathic pain, amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective.
25 Aug, 2022 | 12:14h | UTC
Study Commentary | Is the evidence strong for spinal cord stimulation for diabetic neuropathy? Not all experts agree.
25 Aug, 2022 | 11:52h | UTCOriginal Study: RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses.
24 Aug, 2022 | 14:17h | UTCNews Release: Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses – Cell Press
Original Study: Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance – Cell
Commentary on Twitter
The skinny on non-nutritive sweeteners (they are not inert) via a randomized trial & gut #microbiome assessment: impact is individualized and can impair glycemic responsehttps://t.co/B7CUPy7tMf @CellCellPress @SuezLab @EranElinav @segal_eran @WeizmannScience @Yot_Coh @Elinav_Lab pic.twitter.com/Jz7lUkWlNr
— Eric Topol (@EricTopol) August 19, 2022
Guideline | Management of adults with diabetes on dialysis.
23 Aug, 2022 | 13:16h | UTCManagement of adults with diabetes on dialysis – Joint British Diabetes Societies for Inpatient Care (PDF)
News Release: Latest JBDS dialysis guideline published – Diabetes Times
RCT | A lower glycemic criteria in not better than higher glycemic criteria for the diagnosis of gestational diabetes.
18 Aug, 2022 | 13:04h | UTCLower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Pros and cons with lower vs higher threshold for gestational diabetes diagnosis – medwire News
Commentary on Twitter (thread – click for more)
1/ Overdiagnosis of Gestational Diabetes (GDM): New large randomized trial compared broader/narrower criteria -> NO improvement in mother/baby outcomes BUT x2 increase in % pregnant women labelled as GDM. Time to reconsider GDM testing – https://t.co/xrr0XrdhaZ
— Paul Glasziou (@PaulGlasziou) August 18, 2022
M-A of randomized trials | Effectiveness of exercise intervention during pregnancy on high-risk women for gestational diabetes mellitus prevention.
16 Aug, 2022 | 13:40h | UTC
Guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults.
15 Aug, 2022 | 12:29h | UTCSee related systematic review: The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis – Canadian Journal of Cardiology
Commentary on Twitter (thread – click for more)
https://mobile.twitter.com/CJCJournals/status/1557751107006472193
RCT | Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension.
11 Aug, 2022 | 11:57h | UTCCommentary: Topical Dexamethasone Ophthalmic Suspension OCS-01 Effective in DME Treatment – HCP Live
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022